ChromaDex (CDXC) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
ChromaDex Corporation Reports Third Quarter 2018 Financial Results
November 7, 2018 4:01 PM EST- Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million -
Third Quarter 2018 Highlights vs. Third Quarter 2017
Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%;TRU NIAGEN sales at 84% of NIAGEN-related sales, up from 60%Gross profit as a percentage of net sales improved by 580 basis points to 53.7%;Launched TRU NIAGEN PRO (60ct, 300mg per capsule), the highest dose of NR in a single capsule;Earned certification from NSF International Certified for Sport program; andSigned MOU for creation of a... More